On the upside
Two studies published in the New England Journal of Medicine reported that CombiMatrix's (Nasdaq: CBMX) chromosomal microarray analysis performed better than traditional karyotyping for genetic prenatal diagnosis.
Good Times Restaurant (Nasdaq: GTIM) reported that same store sales climbed 6.8% in November.
On the downside
The Canadian government approved CNOOC's $15 billion acquisition of Nexen (NYSE: NXY).
QR Energy (NYSE: QRE) priced its public offering of 12 million common units at the discounted price of $16.24 per unit.
Sarepta Therapeutics (Nasdaq: SRPT) reported upbeat results from its Duchenne muscular dystrophy treatment eteplirsen but the stock price fell.
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 4 on the NYSE while decliners edged out advancers by more than 5 to 4 on Nasdaq. The Russell 2000 which tracks small cap stocks edged up a fraction 822.